Security key
230031106
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)
CUSIP: 230031106
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 61,676,366
- Total 13F shares
- 62,920,773
- Share change
- +23,568,797
- Total reported value
- $1,097,340,923
- Put/Call ratio
- 21%
- Price per share
- $17.44
- Number of holders
- 134
- Value change
- +$411,767,308
- Number of buys
- 96
- Number of sells
- 42
Report period
Q2 2024
Institutions
134
Top holders
10
CGEM full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Cullinan Therapeutics, Inc. SEC filings
Cullinan Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 230031106
Recent filing periods:
Top shareholders of CGEM - Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MPM BioImpact LLC |
13F
|
Company |
12%
|
7,648,268
|
$130,326,487 | — | 31 Mar 2024 | |
| BVF INC/IL |
13F
|
Company |
5.2%
|
3,196,701
|
$54,471,785 | — | 31 Mar 2024 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
4.7%
|
2,924,842
|
$49,839,308 | — | 31 Mar 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
4.4%
|
2,696,762
|
$45,952,827 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
3.9%
|
2,428,993
|
$41,390,042 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.9%
|
1,774,345
|
$30,234,838 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.3%
|
1,425,459
|
$24,289,821 | — | 31 Mar 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2.2%
|
1,348,015
|
$22,970,176 | — | 31 Mar 2024 | |
| BRAIDWELL LP |
13F
|
Company |
2%
|
1,240,865
|
$21,144,340 | — | 31 Mar 2024 | |
| Nextech Invest Ltd. |
13F
|
Company |
2%
|
1,221,145
|
$20,808,311 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.9%
|
1,152,644
|
$19,641,057 | — | 31 Mar 2024 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.8%
|
1,138,531
|
$19,400,568 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.8%
|
1,109,171
|
$18,900,274 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.6%
|
993,377
|
$16,927,144 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.5%
|
950,000
|
$16,188,000 | — | 31 Mar 2024 | |
| Logos Global Management LP |
13F
|
Company |
1.1%
|
700,000
|
$11,928,000 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
677,330
|
$11,543,654 | — | 31 Mar 2024 | |
| Rubric Capital Management LP |
13F
|
Company |
1%
|
626,929
|
$10,682,870 | — | 31 Mar 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.93%
|
571,138
|
$9,732,192 | — | 31 Mar 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.89%
|
549,276
|
$9,359,663 | — | 31 Mar 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.84%
|
517,606
|
$8,820,006 | — | 31 Mar 2024 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.68%
|
420,217
|
$7,160,497 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.52%
|
321,100
|
$5,472,000 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.43%
|
263,949
|
$4,497,690 | — | 31 Mar 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.42%
|
258,588
|
$4,406,340 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.42%
|
257,873
|
$4,394,156 | — | 31 Mar 2024 | |
| PFM Health Sciences, LP |
13F
|
Company |
0.42%
|
255,967
|
$4,361,678 | — | 31 Mar 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.29%
|
178,396
|
$3,039,868 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.27%
|
169,367
|
$2,886,014 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.27%
|
166,740
|
$2,841,250 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.21%
|
131,349
|
$2,238,187 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.19%
|
115,112
|
$1,961,508 | — | 31 Mar 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.16%
|
97,055
|
$1,653,817 | — | 31 Mar 2024 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.16%
|
95,771
|
$1,631,937 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
94,240
|
$1,605,850 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.15%
|
93,222
|
$1,588,503 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.14%
|
85,574
|
$1,458,181 | — | 31 Mar 2024 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.14%
|
84,234
|
$1,435,347 | — | 31 Mar 2024 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.13%
|
79,680
|
$1,358,000 | — | 31 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.11%
|
68,358
|
$1,164,821 | — | 31 Mar 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.1%
|
61,621
|
$1,050,022 | — | 31 Mar 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.1%
|
60,074
|
$1,023,660 | — | 31 Mar 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.1%
|
59,352
|
$1,011,358 | — | 31 Mar 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.09%
|
57,178
|
$974,313 | — | 31 Mar 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.09%
|
55,888
|
$952,336 | — | 31 Mar 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.08%
|
47,407
|
$807,815 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.08%
|
47,044
|
$801,630 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.08%
|
46,702
|
$795,794 | — | 31 Mar 2024 | |
| Swiss National Bank |
13F
|
Company |
0.08%
|
46,300
|
$788,952 | — | 31 Mar 2024 | |
| CREDIT SUISSE AG/ |
13F
|
Company |
0.07%
|
45,755
|
$779,665 | — | 31 Mar 2024 |
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q2 2024
As of 30 Jun 2024,
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) was held by
134 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
62,920,773 shares.
The largest 10 holders included
MPM BIOIMPACT LLC, BVF INC/IL, BlackRock Inc., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), VANGUARD GROUP INC, FRANKLIN RESOURCES INC, ADAGE CAPITAL PARTNERS GP, L.L.C., Blue Owl Capital Holdings LP, CITADEL ADVISORS LLC, and STATE STREET CORP.
This page lists
134
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
113
Q2 2024 holders
134
Holder diff
21
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.